Reports
Sale
Catheter Related Bloodstream Infections Market Size, Share: By Drug Class: Antibiotics, Non-Antibiotics; By Route of Administration: Oral, Injectables; By Indication: Bacterial Infections, Fungal Infection, Viral and Parasitic Infections; By Distribution Channel: Hospital Pharmacy, Others; Regional Analysis; Supplier Landscape; 2024-2032
Catheter Related Bloodstream Infections Market Size
The catheter related bloodstream infections market was valued at USD 1268.9 million in 2023, driven by the rising hospital admissions and advancements in catheter technology across the 8 major markets. The market is expected to grow at a CAGR of 4.99% during the forecast period of 2024-2032, with the values likely to reach USD 1963.6 million by 2032.
Catheter Related Bloodstream Infections Market Outlook
- The increasing number of hospital admissions and the growing aging population are driving the demand for catheter related bloodstream infection prevention products and treatments.
- One of the major market trends is the rising adoption of antimicrobial-coated catheters to reduce the risk of microbial growth on catheter surfaces.
- The market value is influenced by stringent regulatory guidelines, substantial investment in R&D, and increased focus on training healthcare professionals on best practices of catheter insertion.
Catheter Related Bloodstream Infections Market Overview
Catheter-related bloodstream infections (CRBSI) are primarily caused by the placement of a central venous catheter or arterial line. It is a major factor resulting in hospital-acquired infection and is associated with significant mortality, morbidity, and healthcare costs. The bloodstream infection by a catheter is typically caused by coagulase-negative staphylococci, enterococci, and Candida species, among others. The heightened awareness about the risks of catheter use and the importance of infection control measures is influencing the market landscape for catheter related bloodstream infections. Further, the rising hospital admissions and the growing aging population are major drivers of the market growth. Other factors such as the implementation of strict infection control protocols, advancements in catheter technology, and increased efforts to upgrade the healthcare infrastructure are poised to support market expansion.
Catheter Related Bloodstream Infections Market Growth Drivers
Stringent Regulatory Guidelines on Bloodstream Infection Control to Affect the Market Landscape Significantly
In May 2024, the first global guidelines, aimed at preventing bloodstream infections and others caused as a result of catheter placement in minor blood vessels, was published by the World Health Organization (WHO). These new guidelines comprised 14 good practice statements along with 23 recommendations on major areas for healthcare professionals, including catheter selection, insertion, maintenance, and removal. The implementation of such recommendations is anticipated to encourage healthcare facilities to adopt advanced solutions for infection prevention and control, thereby boosting market growth.
Technological Advancements to Boost Catheter Related Bloodstream Infections Market Demand
In December 2023, the researchers at Texas A&M University (College Station, Texas, United States) reported the development of an innovative catheter dressing that can reduce the severity and frequency of catheter related bloodstream infections. This dressing leverages wireless sensors that can automatically and swiftly detect extremely low levels of bacterial growth on the skin. Such technological advancements are likely to lead to immediate and targeted antibiotic treatments and are expected to fuel market growth in the forecast period.
Catheter Related Bloodstream Infections Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Rising Hospital Admissions | The market is witnessing an increased number of hospital admissions, particularly in intensive care units (ICUs). This is resulting in a growing use of central venous catheters, which are associated with a higher risk of bloodstream infections. Thus, the rising hospital admissions augment the demand for effective prevention and treatment solutions. |
| Adoption of Antimicrobial-Coated Catheters | One of the major market trends is the growing adoption of catheters coated with antimicrobial agents such as silver, chlorhexidine, and other antiseptics to prevent infection. Such coating on catheters helps in reducing microbial growth on its surface and thereby lowers the risk of infection. |
| Investments in R&D | The catheter related bloodstream infections market value is impacted by the rising investment in research and development focused on introducing new antimicrobial agents, better catheter materials, and advanced diagnostic tools. Such investment that aims at accelerating the development of new solutions for CRBSI prevention and management is anticipated to boost market growth. |
| Increased Focus on Training Healthcare Professionals | The market is benefitting from the growing emphasis on training healthcare professionals. Such training programs ensure that the professionals are following best practices for catheter insertion and maintenance and are expected to elevate the market value in the forecast period. |
Catheter Related Bloodstream Infections Market Segmentation
Market Breakup by Drug Class
- Antibiotics
- Cloxacillin
- Ceftazidime
- Cefazoline
- Daptomycin
- Vancomycin
- Teicoplanin
- Echinocandin
- Non-Antibiotics
Market Breakup by Route of Administration
- Oral
- Injectables
Market Breakup by Indication
- Bacterial Infections
- Fungal Infection
- Viral and Parasitic Infections
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Catheter Related Bloodstream Infections Market Share
Market Segmentation Based on Drug Class is Poised to Experience Substantial Growth
The market can be segmented by drug class into non-antibiotics, and antibiotics. The antibiotics segment includes cloxacillin, ceftazidime, cefazoline, daptomycin, vancomycin, teicoplanin, and echinocandin. This segment dominates the market share due to its critical role in treating infections once they occur. The adoption of antibiotics is also fuelled by their targeted action against specific pathogens and the ability of certain antibiotics like daptomycin and vancomycin to treat resistant strains of bacteria commonly involved in catheter-related bloodstream infections.
Catheter Related Bloodstream Infections Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is a major market for catheter related bloodstream infections due to the increased use of central venous catheters in critical care settings and the presence of an advanced healthcare infrastructure. The stringent regulatory guidelines set by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) prompt healthcare providers to adopt effective infection control measures and technologies. Thus, the regulatory framework in the United States contributes to the significant market share of catheter related bloodstream infection prevention products and treatments.
Leading Players in the Catheter Related Bloodstream Infections Market
The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Baxter International
Headquartered in Deerfield (Illinois), Baxter International, an American multinational healthcare company is one of the leading players in the market. Baxter is known for its high-quality products that help reduce the risk of CRBSIs, including advanced intravenous solutions.
Aurobindo Pharma Limited
Indian multinational pharmaceutical manufacturing company Aurobindo Pharma Limited commercializes a broad range of medications, including antibiotics for managing catheter related bloodstream infections. The company manufactures antibiotics, such as ceftazidime and vancomycin, which are widely used to treat bloodstream infections.
Eli Lilly and Company
American pharmaceutical company Eli Lilly and Company leverages its extensive R&D capabilities to develop new antibiotics and improve existing ones in order to treat and prevent the resistant strains of bacteria associated with catheter infections.
Other key players in the market include Fresenius SE & Co. KGaA, GSK PLC, Merck & Co., Inc., Mylan N.V. (Viatris), Pfizer Inc., and Sanofi AG.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Indication |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Catheter Related Bloodstream Infections Market Report
- What was the catheter related bloodstream infections market value in 2023?
- What is the catheter related bloodstream infections market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on drug class?
- What is the market breakup based on the route of administration?
- What is the market breakup by indication?
- Who are the major distribution channels in the market?
- What are the major factors aiding the catheter related bloodstream infections market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major catheter related bloodstream infections market trends?
- How does the rise in the geriatric population impact the market size?
- Which drug class will dominate the market share?
- Which route of administration is expected to have a high market value in the coming years?
- Which distribution channel will experience the highest demand in the market segment?
- Which indication is projected to contribute to the highest market growth?
- Who are the key players involved in the catheter related bloodstream infections market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Catheter Related Bloodstream Infections Market Overview: 8 Major Market
3.1 Catheter Related Bloodstream Infections Market Historical Value (2017-2023)
3.2 Catheter Related Bloodstream Infections Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Catheter Related Bloodstream Infections Market: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Catheter Related Bloodstream Infections Market Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Catheter Related Bloodstream Infections Market Landscape: 8 Major Market*
8.1 Catheter Related Bloodstream Infections Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Catheter Related Bloodstream Infections Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Route of Administration
9 Catheter Related Bloodstream Infections Market Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Global Catheter Related Bloodstream Infections: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Catheter Related Bloodstream Infections Market Segmentation: 8 Major Markets
12.1 Catheter Related Bloodstream Infections Market (2017-2032) by Drug Class
12.1.1 Market Overview
12.1.2 Antibiotics
12.1.2.1 Cloxacillin
12.1.2.2 Ceftazidime
12.1.2.3 Cefazoline
12.1.2.4 Daptomycin
12.1.2.5 Vancomycin
12.1.2.6 Teicoplanin
12.1.2.7 Echinocandin
12.1.3 Non-Antibiotics
12.2 Catheter Related Bloodstream Infections Market (2017-2032) by Route of Administration
12.2.1 Market Overview
12.2.2 Oral
12.2.3 Injectables
12.3 Catheter Related Bloodstream Infections Market (2017-2032) by Indication
12.3.1 Market Overview
12.3.2 Bacterial Infections
12.3.3 Fungal Infection
12.3.4 Viral and Parasitic Infections
12.4 Catheter Related Bloodstream Infections Market (2017-2032) by Distribution Channel
12.4.1 Market Overview
12.4.2 Hospital Pharmacy
12.4.3 Retail Pharmacy
12.4.4 Online Pharmacy
12.5 Catheter Related Bloodstream Infections Market by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
12.5.5 India
13 United States Catheter Related Bloodstream Infections Market (2017-2032)
13.1 United States Catheter Related Bloodstream Infections Market Historical Value (2017-2023)
13.2 United States Catheter Related Bloodstream Infections Market Forecast Value (2024-2032)
13.3 United States Catheter Related Bloodstream Infections Market (2017-2032) by Drug Class
13.3.1 Market Overview
13.3.2 Antibiotics
13.3.2.1 Cloxacillin
13.3.2.2 Ceftazidime
13.3.2.3 Cefazoline
13.3.2.4 Daptomycin
13.3.2.5 Vancomycin
13.3.2.6 Teicoplanin
13.3.2.7 Echinocandin
13.3.3 Non-Antibiotics
13.4 United States Catheter Related Bloodstream Infections Market (2017-2032) by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Injectables
13.5 United States Catheter Related Bloodstream Infections Market (2017-2032) by Indication
13.5.1 Market Overview
13.5.2 Bacterial Infections
13.5.3 Fungal Infection
13.5.4 Viral and Parasitic Infections
13.6 United States Catheter Related Bloodstream Infections Market (2017-2032) by Distribution Channel
13.6.1 Market Overview
13.6.2 Hospital Pharmacy
13.6.3 Retail Pharmacy
13.6.4 Online Pharmacy
14 EU-4 and United Kingdom Catheter Related Bloodstream Infections Market (2017-2032)
14.1 EU-4 and United Kingdom Catheter Related Bloodstream Infections Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Catheter Related Bloodstream Infections Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Catheter Related Bloodstream Infections Market (2017-2032) by Drug Class
14.3.1 Market Overview
14.3.2 Antibiotics
14.3.2.1 Cloxacillin
14.3.2.2 Ceftazidime
14.3.2.3 Cefazoline
14.3.2.4 Daptomycin
14.3.2.5 Vancomycin
14.3.2.6 Teicoplanin
14.3.2.7 Echinocandin
14.3.3 Non-Antibiotics
14.4 EU-4 and United Kingdom Catheter Related Bloodstream Infections Market (2017-2032) by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Injectables
14.5 EU-4 and United Kingdom Catheter Related Bloodstream Infections Market (2017-2032) by Indication
14.5.1 Market Overview
14.5.2 Bacterial Infections
14.5.3 Fungal Infection
14.5.4 Viral and Parasitic Infections
14.6 EU-4 and United Kingdom Catheter Related Bloodstream Infections Market (2017-2032) by Distribution Channel
14.6.1 Market Overview
14.6.2 Hospital Pharmacy
14.6.3 Retail Pharmacy
14.6.4 Online Pharmacy
15 Japan Catheter Related Bloodstream Infections Market
15.1 Japan Catheter Related Bloodstream Infections Market Historical Value (2017-2023)
15.2 Japan Catheter Related Bloodstream Infections Market Forecast Value (2024-2032)
15.3 Japan Catheter Related Bloodstream Infections Market (2017-2032) by Drug Class
15.3.1 Market Overview
15.3.2 Antibiotics
15.3.2.1 Cloxacillin
15.3.2.2 Ceftazidime
15.3.2.3 Cefazoline
15.3.2.4 Daptomycin
15.3.2.5 Vancomycin
15.3.2.6 Teicoplanin
15.3.2.7 Echinocandin
15.3.3 Non-Antibiotics
15.4 Japan Catheter Related Bloodstream Infections Market (2017-2032) by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Injectables
15.5 Japan Catheter Related Bloodstream Infections Market (2017-2032) by Indication
15.5.1 Market Overview
15.5.2 Bacterial Infections
15.5.3 Fungal Infection
15.5.4 Viral and Parasitic Infections
15.6 Japan Catheter Related Bloodstream Infections Market (2017-2032) by Distribution Channel
15.6.1 Market Overview
15.6.2 Hospital Pharmacy
15.6.3 Retail Pharmacy
15.6.4 Online Pharmacy
16 India Catheter Related Bloodstream Infections Market
16.1 India Catheter Related Bloodstream Infections Market (2017-2032) Historical Value (2017-2023)
16.2 India Catheter Related Bloodstream Infections Market (2017-2032) Forecast Value (2024-2032)
16.3 India Catheter Related Bloodstream Infections Market (2017-2032) by Drug Class
16.3.1 Market Overview
16.3.2 Antibiotics
16.3.2.1 Cloxacillin
16.3.2.2 Ceftazidime
16.3.2.3 Cefazoline
16.3.2.4 Daptomycin
16.3.2.5 Vancomycin
16.3.2.6 Teicoplanin
16.3.2.7 Echinocandin
16.3.3 Non-Antibiotics
16.4 India Catheter Related Bloodstream Infections Market (2017-2032) by Route of Administration
16.4.1 Market Overview
16.4.2 Oral
16.4.3 Injectables
16.5 India Catheter Related Bloodstream Infections Market (2017-2032) by Indication
16.5.1 Market Overview
16.5.2 Bacterial Infections
16.5.3 Fungal Infection
16.5.4 Viral and Parasitic Infections
16.6 India Catheter Related Bloodstream Infections Market (2017-2032) by Distribution Channel
16.6.1 Market Overview
16.6.2 Hospital Pharmacy
16.6.3 Retail Pharmacy
16.6.4 Online Pharmacy
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Baxter International Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisition
23.2.5 Certifications
23.3 Aurobindo Pharma Limited
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisition
23.3.5 Certifications
23.4 Eli Lilly and Company
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisition
23.4.5 Certifications
23.5 Fresenius SE & Co. KGaA
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisition
23.5.5 Certifications
23.6 GSK PLC
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisition
23.6.5 Certifications
23.7 Merck & Co., Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisition
23.7.5 Certifications
23.8 Mylan N.V. (Viatris)
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisition
23.8.5 Certifications
23.9 Pfizer Inc
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisition
23.9.5 Certifications
23.10 Sanofi AG
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisition
23.10.5 Certifications
23.11 Teva Pharmaceutical Industries Ltd.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisition
23.11.5 Certifications
23.12 TauroPhar GmbH
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisition
23.12.5 Certifications
23.13 Xellia Pharmaceuticals Ltd.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisition
23.13.5 Certifications
24 Catheter Related Bloodstream Infections Market – Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER